Patel, Ami
DiGiandomenico, Antonio
Keller, Ashley E.
Smith, Trevor R. F.
Park, Daniel H.
Ramos, Stephanie
Schultheis, Katherine http://orcid.org/0000-0001-9232-1888
Elliott, Sarah T. C.
Mendoza, Janess
Broderick, Kate E.
Wise, Megan C.
Yan, Jian
Jiang, Jingjing
Flingai, Seleeke
Khan, Amir S.
Muthumani, Kar
Humeau, Laurent
Cheng, Lily I.
Wachter-Rosati, Leslie
Stover, C. Kendall http://orcid.org/0000-0002-7406-1696
Sardesai, Niranjan Y.
Weiner, David B.
Article History
Received: 4 January 2017
Accepted: 10 July 2017
First Online: 21 September 2017
Competing interests
: K.M. reports receiving grants from DARPA and Inovio, receiving consulting fees from Inovio related to DNA vaccine development, and a pending patent application (to Inovio) for delivery of DNA-encoded monoclonal antibodies (PCT Patent Application No. PCT/US17/31449, “DNA Antibody Constructs for Use against <i>Pseudomonas aeuruginosa</i>”). T.R.F.S., S.R., J.M., K.E.B., K.S., J.Y., J.J., A.S.K., L.H., and N.Y.S. are employees of Inovio Pharmaceuticals and as such receive salary and benefits, including ownership of stock and stock option, from the company. D.B.W. has received grant funding, participates in industry collaborations, has received speaking honoraria, and has received fees for consulting, including serving on scientific review committees and board services. Remuneration received by D.B.W. includes direct payments or stock or stock options, and in the interest of disclosure he notes potential conflicts associated with this work with Inovio and possibly others. In addition, he has a patent DNA vaccine delivery pending to Inovio (see above). A.D., A.E.K., L.I.C., L.W.-R., C.K.S. are employees of MedImmune/AstraZeneca and may own stock in the company. All remaining authors declare no competing financial interests.